MStranslate logo
Log In
Lost your password?
Lost Password
Back to login
Search
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us
Breaking
  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast - Episode Library
  • Patient Community Day at ECTRIMS 2025
  • Multiple Sclerosis in 2025 – Key Developments to Date
  • HOME
  • Research
    • Basic Sciences
      • B Cells
    • Conferences
      • AAN
      • ACTRIMS
      • ECTRIMS
      • MS Virtual
    • COVID-19
    • Epstein-Barr virus
    • Genetics
    • Gut Microbiome
    • Hormones
    • Lifestyle
      • Diet
      • Exercise
      • Jelinek Group
      • Vitamin D
    • Medicinal Cannabis
    • Mental Health
    • Progressive MS
    • Remyelination
    • Stem Cells
    • Symptoms
      • Cognition
      • Fatigue
      • Quality of Life
      • Rehabilitation
  • Treatments
    • Alemtuzumab
    • Daclizumab
    • Dimethyl fumarate
    • Fingolimod
    • Interferon-Beta
    • Laquinimod
    • Natalizumab
    • Ocrelizumab
    • Clinical Trials & Studies
      • MIS416
  • Lifestyle
  • Collaborations
    • Dr Sally Shaw
    • Dr Travis Stiles
    • Employment & MS
    • Kriesel Lab
    • MBC@RMH
      • MSBase@MBC
      • PrevANZ
      • Neuroimaging
      • Basic Sciences
      • Ocular Motor
      • Movement Disorders & Rehabilitation
    • MitoQ
    • Multiple Sclerosis Limited
  • Connect
    • Live Research Q&A
  • About MStranslate
    • THE TEAM
    • THE APPROACH
    • VALUES & STANDARDS
  • Contact Us

Tagged fake news

fake news

FAKE NEWS ALERT: COVID Vaccines & MS

MStranslate
June 2, 2021
Research, Understanding Science
4 Comments
If you have been following MStranslate for a while, you will know that one of my pet hates is the poor reporting of multiple sclerosis research...

Recent Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Recent Comments

  • FDA Decision On Tolebrutinib - MStranslate on Multiple Sclerosis in 2025 – Key Developments to Date
  • Treatment With Gut Bacteria Shows Benefits In New Study on Gut Bacteria in People Living with RRMS
  • Community Q&A: COVID-19 Vaccines & Multiple Sclerosis on Community Q&A: The Blood-Brain Barrier
  • Community Q&A: Why Don't We Have A Multiple Sclerosis Cure? on Community Q&A: COVID-19 Vaccines & MS
  • Tim Little on FAKE NEWS ALERT: COVID Vaccines & MS

Calendar

March 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
« Jan    

Archives

Categories

Posts

  • FDA Decision On Tolebrutinib
  • Multiple Sclerosis Research In 2026
  • Revisiting ECTRIMS Congress 2025
  • UPDATED: The ECTRIMS Podcast – Episode Library
  • Patient Community Day at ECTRIMS 2025

Google+

Get social

Copyright 2014-2018 MStranslate. All Rights Reserved. Contact Us
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.